Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MARIPOSA-2: Is the treatment worse than the disease?

Med (New York, N.Y.) - 9 Feb 2024

Lee Alexandria T M, Ou Sai-Hong Ignatius

Abstract excerpt

Passaro et al.1 demonstrated in EGFR+ NSCLC post-1L osimertinib both "quad" (lazertinib [L] + amivantamab [A] + chemotherapy [CP]) and "triplet" (ACP) regimens achieved improved median progression-free survival over CP. Nonetheless, a high incidence of adverse events requiring dose modifications may limit adaptation of the triplet and quad MARIPOSA-2 regimens.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors
Share to CP gene

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Source

Identifiers

PMID: 38340706
DOI: 10.1016/j.medj.2023.12.010

Genes

CP
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MARIPOSA-2: Is the treatment worse than the disease?PMID 38340706Read ↗

MA12.07 Amivantamab Plus Lazertinib vs Osimertinib in First-Line, EGFR-Mutant Advanced NSCLC: Patient-relevant Outcomes from MARIPOSASemantic proximity Read ↗

Amivantamab Plus Lazertinib and Platin-Based Chemotherapy Plus Osimertinib in EGFR-Mutant NSCLC: How to Choose Among Them and When Is Monotherapy with Osimertinib Still the Best Option?Semantic proximity Read ↗

EGFR-Mutant NSCLC: Spotlight on Amivantamab.Semantic proximity Read ↗

Patient-Relevant Outcomes From the Phase III MARIPOSA-2 Trial: Amivantamab-Chemotherapy Versus Chemotherapy in EGFR-Mutant Advanced Non-Small-Cell Lung Cancer Following Disease Progression on Osimertinib.Semantic proximity Read ↗

EGFR-Mutant NSCLC: Chemo-TKI Bests TKI.Semantic proximity Read ↗

An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations.Semantic proximity Read ↗

A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS study.Semantic proximity Read ↗

Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC.Semantic proximity Read ↗

Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.Semantic proximity Read ↗

Amivantamab compared with real-world therapies in patients with advanced non-small cell lung cancer harboring EGFR exon 20 insertion mutations who progressed after platinum-based chemotherapy.Semantic proximity Read ↗

Amivantamab Emerges Positively from Its "Chrysalis".Semantic proximity Read ↗

Should we be surprised at the paucity of response to EGFR inhibitors?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.